ALNY

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

423.47

USD

$0.00

(

0.00%

)

At Close (As of Nov 4, 2025)

$55.95B

Market Cap

1411.57

P/E Ratio

0.3

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.3B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $1B
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.70%
$15.46
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
NVDA
-1.61%
$195.48
GPUS
+8.87%
$0.38
RUBI
-49.75%
$0.30
PFE
+1.29%
$24.61
ETHD
+20.91%
$5.26
YDKG
-6.48%
$0.05
SLDP
+52.09%
$8.53
SMX
+38.80%
$2.04
T
-0.36%
$24.44
PLUG
+3.82%
$2.61
TSLA
+3.71%
$460.75
PLTR
-1.60%
$187.67
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
F
+2.85%
$13.15
PINS
-22.92%
$25.36
AAL
+6.08%
$13.42
BITF
+6.11%
$4.07
AMD
+3.26%
$258.22
WTO
-1.40%
$0.04
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
SNAP
-2.45%
$7.28
VALE
-2.13%
$11.94
ACHR
-0.15%
$9.54
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
CIFR
+7.64%
$24.22
ONDS
-0.25%
$5.94
NFE
+13.99%
$1.53
SOFI
+3.06%
$30.27
RXRX
-8.08%
$5.00
DVLT
-7.83%
$1.64
MARA
+3.70%
$17.23
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
RIG
+0.38%
$3.91
BAC
-1.33%
$52.82
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
BURU
-0.82%
$0.28
CAN
+14.43%
$1.27
BTBT
+3.14%
$3.28
EPWK
-7.75%
$0.06
FUBO
+11.27%
$4.09
SRM
+53.27%
$10.30
IREN
+12.86%
$75.19
TLRY
+3.62%
$1.28
NVO
+1.01%
$48.73
ZDAI
+13.94%
$0.52
U
+17.45%
$42.13
HIMS
+3.11%
$44.12
APPS
+23.14%
$7.29
ALIT
-7.22%
$2.50
BMNR
+4.96%
$41.42
BTG
+1.12%
$4.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
RGTI
+7.60%
$37.85
NIO
+2.30%
$7.32
WLGS
-5.57%
$0.04
NOK
+0.73%
$6.86
RIOT
-2.90%
$18.71
PCG
+1.05%
$16.32
HTZ
-2.37%
$6.57
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
NCLH
-1.25%
$18.55
AMZN
-0.36%
$248.42
BW
+38.55%
$5.18
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
GOOGL
+2.47%
$284.42
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
PLTD
+1.97%
$6.47
PLTZ
+2.69%
$6.23
AG
-6.35%
$10.82
NVTS
-6.07%
$9.82
AFMD
-34.94%
$0.18
AMCR
+2.22%
$8.04
BBD
+3.16%
$3.51
ABEV
+1.04%
$2.41
CMBM
-12.03%
$2.85
MSPR
-30.73%
$0.45
HBAN
-0.65%
$15.27
CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.70%
$15.46
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
NVDA
-1.61%
$195.48
GPUS
+8.87%
$0.38
RUBI
-49.75%
$0.30
PFE
+1.29%
$24.61
ETHD
+20.91%
$5.26
YDKG
-6.48%
$0.05
SLDP
+52.09%
$8.53
SMX
+38.80%
$2.04
T
-0.36%
$24.44
PLUG
+3.82%
$2.61
TSLA
+3.71%
$460.75
PLTR
-1.60%
$187.67
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
F
+2.85%
$13.15
PINS
-22.92%
$25.36
AAL
+6.08%
$13.42
BITF
+6.11%
$4.07
AMD
+3.26%
$258.22
WTO
-1.40%
$0.04
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
SNAP
-2.45%
$7.28
VALE
-2.13%
$11.94
ACHR
-0.15%
$9.54
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
CIFR
+7.64%
$24.22
ONDS
-0.25%
$5.94
NFE
+13.99%
$1.53
SOFI
+3.06%
$30.27
RXRX
-8.08%
$5.00
DVLT
-7.83%
$1.64
MARA
+3.70%
$17.23
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
RIG
+0.38%
$3.91
BAC
-1.33%
$52.82
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
BURU
-0.82%
$0.28
CAN
+14.43%
$1.27
BTBT
+3.14%
$3.28
EPWK
-7.75%
$0.06
FUBO
+11.27%
$4.09
SRM
+53.27%
$10.30
IREN
+12.86%
$75.19
TLRY
+3.62%
$1.28
NVO
+1.01%
$48.73
ZDAI
+13.94%
$0.52
U
+17.45%
$42.13
HIMS
+3.11%
$44.12
APPS
+23.14%
$7.29
ALIT
-7.22%
$2.50
BMNR
+4.96%
$41.42
BTG
+1.12%
$4.04
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
RGTI
+7.60%
$37.85
NIO
+2.30%
$7.32
WLGS
-5.57%
$0.04
NOK
+0.73%
$6.86
RIOT
-2.90%
$18.71
PCG
+1.05%
$16.32
HTZ
-2.37%
$6.57
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
NCLH
-1.25%
$18.55
AMZN
-0.36%
$248.42
BW
+38.55%
$5.18
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
GOOGL
+2.47%
$284.42
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
PLTD
+1.97%
$6.47
PLTZ
+2.69%
$6.23
AG
-6.35%
$10.82
NVTS
-6.07%
$9.82
AFMD
-34.94%
$0.18
AMCR
+2.22%
$8.04
BBD
+3.16%
$3.51
ABEV
+1.04%
$2.41
CMBM
-12.03%
$2.85
MSPR
-30.73%
$0.45
HBAN
-0.65%
$15.27
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.